Atrium Therapeutics Stock Forward View - Simple Moving Average
| RNADelisted Stock | USD 14.54 -0.26 -1.76% |
Momentum
Sell Peaked
Oversold | Overbought |
This view connects Atrium Therapeutics Common headline attention with price response and peer context.
The Simple Moving Average forecasted value of Atrium Therapeutics Common on the next trading day is expected to be 14.54 with a mean absolute deviation of 1.62 and the sum of the absolute errors of 95.54.Atrium Therapeutics after-hype prediction price | $ 14.68 |
Hype metrics are shown as one component among forecasting, technical, analyst, and earnings context.
Atrium |
Atrium Therapeutics Additional Predictive Modules
Most predictive techniques to examine Atrium price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Atrium using various technical indicators. When you analyze Atrium charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Moving Average Price Forecast For the 16th of March 2026
Given 90 days horizon, the Simple Moving Average forecasted value of Atrium Therapeutics Common on the next trading day is expected to be 14.54 with a mean absolute deviation of 1.62 , mean absolute percentage error of 71.35 , and the sum of the absolute errors of 95.54 .Please note that although there have been many attempts to predict Atrium Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Atrium Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Atrium Therapeutics | Atrium Therapeutics Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Atrium Therapeutics Common uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of Atrium Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Atrium Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 118.7023 |
| Bias | Arithmetic mean of the errors | 1.4592 |
| MAD | Mean absolute deviation | 1.6193 |
| MAPE | Mean absolute percentage error | 0.1057 |
| SAE | Sum of the absolute errors | 95.54 |
Mean reversion opportunities in Atrium Therapeutics' arise when market prices disconnect from fundamental anchors such as earnings, book value, or historical price-to-earnings multiples.
After-Hype Price Density Analysis
Using probability distributions for Atrium Therapeutics forecasting acknowledges that no model can consistently predict Atrium Therapeutics' exact future price. The distribution approach quantifies model uncertainty and helps investors avoid overconfidence in any single forecast.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The after-hype price analysis for Atrium Therapeutics provides a news-conditional view of potential price outcomes. Atrium Therapeutics' after-hype downside and upside margins for the prediction period are 4.37 and 24.99, respectively. This analysis complements technical and fundamental research by adding a news-sentiment dimension to Atrium Therapeutics' price forecasting.
Current Value
The after-hype framework applied to Atrium Therapeutics Common assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Atrium Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atrium Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Atrium Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.30 | 10.31 | 0.14 | 5.18 | 12 Events | 8 Events | In 12 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
14.54 | 14.68 | 0.96 |
|
Hype Timeline
On the 15th of March 2026 Atrium Therapeutics is traded for 14.54. The company has historical hype elasticity of 0.14, and average elasticity to hype of competition of 5.18. Atrium is estimated to increase in value after the next headline, with the price projected to jump to 14.68 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 0.96%, whereas the daily expected return is at this time at -1.3%. The volatility of related hype on Atrium Therapeutics is about 258.85%, with the expected price after the next announcement by competition of 19.72. The company reported last year's revenue of 18.75 M. Reported Net Loss for the year was -684.63 M with loss before taxes, overhead, and interest of -540.4 M. Considering the 90-day investment horizon the next estimated press release will be in 12 days. Cross-verify projections for Atrium Therapeutics using Historical Fundamental Analysis of Atrium Therapeutics. The view provides historical context for the projection set.Related Hype Analysis
The peer hype comparison table for Atrium Therapeutics includes downside risk metrics such as value-at-risk and maximum drawdown for Atrium Therapeutics' competitors. providing context for assessing the relative risk profile of a Atrium Therapeutics investment.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| JAZZ | Jazz Pharmaceuticals PLC | 5.34 | 8 per month | 2.00 | 0.06 | 1.85 | -3.95 | 17.22 | |
| MDGL | Madrigal Pharmaceuticals | 13.59 | 10 per month | 0.00 | -0.11 | 3.41 | -3.53 | 19.67 | |
| CAI | Caris Life Sciences | 0.74 | 9 per month | 0.00 | -0.17 | 3.53 | -6.33 | 17.67 | |
| MRNA | Moderna | 2.69 | 9 per month | 3.22 | 0.22 | 10.85 | -5.95 | 23.89 | |
| MRUS | Merus BV | -0.06 | 7 per month | 0.60 | 0.12 | 0.51 | -0.23 | 36.44 | |
| ABVX | Abivax SA American | 3.97 | 7 per month | 3.72 | 0.03 | 6.20 | -6.57 | 29.38 | |
| CYTK | Cytokinetics | 16.83 | 6 per month | 0.00 | -0.01 | 3.98 | -3.95 | 15.74 | |
| NUVL | Nuvalent | 1.98 | 11 per month | 0.00 | -0.03 | 2.93 | -3.90 | 15.70 | |
| TECH | Bio Techne Corp | -1.32 | 10 per month | 0.00 | -0.08 | 3.56 | -4.01 | 12.41 | |
| RYTM | Rhythm Pharmaceuticals | -3.93 | 9 per month | 0.00 | -0.06 | 4.55 | -5.14 | 18.69 |
Other Forecasting Options for Atrium Therapeutics
The movement of Atrium price is the central consideration for investors deciding whether to enter or hold a position. Noise in Atrium Stock price charts can make it difficult to distinguish meaningful trends from random fluctuations.Atrium Therapeutics Related Equities
The following equities are related to Atrium Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Atrium Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Atrium Therapeutics Market Strength Events
Investors use market strength indicators for Atrium Therapeutics to evaluate how the stock performs relative to broader market trends. These indicators support more precise timing of Atrium Therapeutics Common positions, helping investors maximize return and minimize poorly-timed trades.
Atrium Therapeutics Risk Indicators
A careful analysis of Atrium Therapeutics' basic risk indicators helps investors understand the risk environment surrounding atrium stock. This understanding is an essential input for forecasting Atrium Therapeutics' future price and for deciding how to manage the associated investment risk.
| Mean Deviation | 2.65 | |||
| Standard Deviation | 9.91 | |||
| Variance | 98.28 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Atrium Therapeutics
Coverage intensity for Atrium Therapeutics Common matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Atrium Therapeutics Short Properties
Short sentiment tied to Atrium Therapeutics Common matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 137.7 M | |
| Cash And Short Term Investments | 1.7 B |
Cross-verify projections for Atrium Therapeutics using Historical Fundamental Analysis of Atrium Therapeutics. The view provides historical context for the projection set. Analysis related to Atrium Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Atrium Stock
Atrium Therapeutics liquidity profile may be thinner following delisting.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |